Charles Schwab Investment Management Inc Halozyme Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,773,397 shares of HALO stock, worth $99.8 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,773,397
Previous 1,787,548
0.79%
Holding current value
$99.8 Million
Previous $93.6 Million
8.4%
% of portfolio
0.02%
Previous 0.02%
Shares
29 transactions
Others Institutions Holding HALO
# of Institutions
538Shares Held
123MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$992 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$726 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$373 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$229 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$192 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.84B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...